Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc.
Metsera Inc. (MTSR)
Market is closed
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 789,998 | $14,219,964.00 | 8,313,680 | 2025-02-03 | Filing | |
| $18.00 | 1,432,224 | $25,780,032.00 | 18,503,128 | 2025-02-03 | Filing | |
| $18.00 | 789,998 | $14,219,964.00 | 8,313,680 | 2025-02-03 | Filing | |
| $18.00 | 789,998 | $14,219,964.00 | 8,313,680 | 2025-02-03 | Filing | |
| $18.00 | 1,432,224 | $25,780,032.00 | 18,503,128 | 2025-02-03 | Filing |
News See All
13 Biotech Stocks with Huge Upside Potential
The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce reductions.
10 Stocks Insiders Spent The Most Money On Recently
As the broader market continues to rise this year, we thought it would be interesting to highlight some stocks that have seen significant insider buying recently.
Billionaire Hedge Funds
